Key terms
About GH
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GH news
Nov 11
8:19am ET
Morgan Stanley Remains a Buy on Guardant Health (GH)
Nov 08
7:59am ET
Guardant Health (GH) Gets a Buy from Scotiabank
Nov 07
9:40am ET
Stifel Nicolaus Remains a Buy on Guardant Health (GH)
Nov 07
9:00am ET
Craig-Hallum Remains a Buy on Guardant Health (GH)
Nov 07
8:42am ET
Guardant Health: Strong Buy Rating Backed by Robust Growth and Strategic Advancements
Nov 07
6:55am ET
Guardant Health: Strong Financial Performance and Strategic Growth Potential Earns Buy Rating
Nov 07
6:44am ET
Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)
Nov 07
12:16am ET
Guardant Health: Strong Financial Performance and Growth Prospects Lead to Buy Rating
Nov 06
11:26pm ET
Guardant Health Boosts 2024 Revenue Outlook
Nov 06
7:30pm ET
Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
Nov 06
4:17pm ET
Guardant Health reports Q3 EPS (45c), consensus (74c)
Nov 06
4:16pm ET
Guardant Health raises FY24 revenue view to $720M-$725M, consensus $695.2M
Oct 31
9:17am ET
Morgan Stanley Reaffirms Their Buy Rating on Guardant Health (GH)
Oct 30
6:37am ET
Guardant Health price target lowered to $35 from $40 at Bernstein
Oct 24
5:32pm ET
Guardant Health Appoints Roberto Mignone to Board
Oct 23
8:55am ET
Craig-Hallum Keeps Their Buy Rating on Guardant Health (GH)
Oct 17
7:30am ET
Guardant Health price target lowered to $50 from $60 at Leerink
Sep 18
8:21am ET
Guardant Health publishes SCRUM-Japan GOZILA study results
Sep 17
6:38am ET
Buy Rating on Guardant Health: Significant Market Opportunity and Competitive Edge
Sep 12
6:20am ET
Exact Sciences added to ‘Tactical Outperform List’ at Evercore ISI
Sep 10
8:22am ET
Guardant Health, Italy’s Policlinico Gemelli team on liquid biopsy testing
Sep 04
11:35am ET
Guardant Health management to meet with Craig-Hallum
Aug 23
4:28pm ET
Guardant Health enters open market sale agreement for up to $400M in stock
Aug 22
7:46am ET
Scotiabank Keeps Their Buy Rating on Guardant Health (GH)
Aug 21
6:39am ET
Guardant Health price target raised to $40 from $32 at UBS
Aug 13
8:33am ET
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Prime Medicine, Inc. (PRME)
Aug 13
6:48am ET
Guardant Health (GH) Gets a Buy from Piper Sandler
Aug 13
6:35am ET
Guardant Health price target raised to $34 from $30 at Piper Sandler
Nov 06
8:00pm ET
Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Nov 06
6:15pm ET
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
Nov 05
9:15am ET
Unveiling Guardant Health (GH) Q3 Outlook: Wall Street Estimates for Key Metrics
Oct 30
10:01am ET
Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know
GH Financials
Key terms
Ad Feedback
GH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
